Article
Is there an improvement in the prognosis of hypopharyngeal carcinoma in the last 35 years?
Search Medline for
Authors
Published: | July 8, 2008 |
---|
Outline
Text
Within the group of head and neck cancer hypopharyngeal carcinoma shows the worst prognosis. While radical procedures such as laryngopharyngectomies were performed in the past, today definitive concomitant chemoradiotherapy is state-of-the-art in advanced hypopharyngeal cancer if surgery with preservation of the larynx seems not possible.
Between 1970 and 2005 968 patients (55,1±9,7 years, male to female ratio 11:1) with hypopharyngeal cancer were treated. Concomitant chemoradiotherapy was introduced in clinical practice in 1968 for definitive and for postoperative adjuvant treatment.
Within the years a slight increase in age and female proportion was observed.
Recurrence free survival was calculated in 5 year intervals: 1970-75, 20,3%, 1976-1980, 23,5%, 1981-1985, 31,5%, 1986-1990, 35,8%, 1991-1995, 43,2% and 1996-2000, 40,3%. The latest series from 2001-2001 shows currently a survival rate of 58,9%. The increase of survival correlates with the application of concurrent chemoradiotherapy. Therefore, concurrent chemoradiotherapy defines the new standard in treatment of hypopharyngeal cancer.